Idorsia Pharmaceuticals Ltd is a biopharmaceutical company that conducts drug discovery, clinical development, and commercial operations to provide transformative treatments for patients. The company focuses on researching and developing therapeutic products and vaccines targeting conditions such as insomnia, hypertension, and Fabry disease.
Subscribe to see Idorsia Pharmaceuticals Ltd’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Idorsia Pharmaceuticals Ltd is a pharmaceuticals, biotech company headquartered in Switzerland. Xcout tracks 11 named people at Idorsia Pharmaceuticals Ltd, including Jean-Paul Clozel (Chairman of the Board, interim CEO).
5 more named people on record for Idorsia Pharmaceuticals Ltd, with roles, board committees and tenure — see the full roster →
A few of Idorsia Pharmaceuticals Ltd's closest competitors — see the full list of competitors and alternatives →
Ipsen is a global biopharmaceutical company that researches, develops, and commercializes innovative medicines. It primarily serves patients suffering from conditions in the fields of oncology, rare diseases, and neuroscience.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing and commercializing therapeutic solutions that address critical unmet medical needs. The company currently offers two approved treatments: HETLIOZ, prescribed for non-24-hour sleep-wake disorders, and Fanapt oral tablets, used in the management of schizophrenia. Vanda maintains an active and diverse development pipeline, exploring new applications for its existing therapies and advancing a range of novel compounds. This includes expanding HETLIOZ (tasimelteon) to potentially treat conditions such as jet lag disorder, Smith-Magenis Syndrome, pediatric Non-24, autism spectrum disorder, and delayed sleep phase disorder. Fanapt (iloperidone) is being investigated for bipolar disorder, alongside the creation of a long-acting injectable formulation for schizophrenia. Other promising candidates in development include: Tradipitant (VLY-686): A small molecule neurokinin-1 receptor (NK-1R) antagonist for atopic dermatitis, gastroparesis, and motion sickness. VTR-297: A small molecule histone deacetylase inhibitor, primarily for hematologic malignancies but with broader oncology potential. VQW-765: A small molecule nicotinic acetylcholine receptor partial agonist targeting psychiatric disorders. A portfolio of cystic fibrosis transmembrane conductance regulator (CFTR) activators and inhibitors aimed at dry eye and ocular inflammation. BPO-27: For secretory diarrhea disorders, including cholera. VHX-896: The active metabolite of iloperidone. Vanda Pharmaceuticals Inc. markets its products in the United States, Europe, and Israel. The company was established in 2002 and is headquartered in Washington, D.C.
Novartis is a global healthcare company that researches, develops, and manufactures innovative medicines across therapeutic areas such as oncology, immunology, neuroscience, and cardiovascular diseases. The company serves patients, healthcare professionals, and healthcare systems worldwide by providing pharmaceutical treatments and managing clinical trials.
Chiesi Farmaceutici is a global biopharmaceutical group that researches, develops, and commercializes therapeutic solutions for patients. The company focuses primarily on respiratory health, rare diseases, and specialty care.
Island Pharmaceuticals Ltd is an Australian antiviral drug development company based in Melbourne, Australia, focused on addressing infectious diseases.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Post the link and the card appears automatically — each network fetches the image itself.